Cumberland Pharmaceuticals Inc (CPIX) stock
CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 5/3074% above fair value
$6.12+0.82 (+15.47%)
Close on Nov 11, 2026Market cap $91.70MP/E –Yield –
Cumberland Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Cumberland Pharmaceuticals's gross margin for the twelve months ending Mar 31, 2026 was 77.2%. For fiscal 2025 it was 85.0%, against 82.6% the year before. The highest annual figure on record is 92.2% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 85.0% | +2.4 |
| FY2024 | Dec 31, 2024 | 82.6% | −2.1 |
| FY2023 | Dec 31, 2023 | 84.7% | +6.4 |
| FY2022 | Dec 31, 2022 | 78.3% | +2.8 |
| FY2021 | Dec 31, 2021 | 75.5% | −1.4 |
| FY2020 | Dec 31, 2020 | 76.9% | −1.5 |
| FY2019 | Dec 31, 2019 | 78.4% | −1.1 |
| FY2018 | Dec 31, 2018 | 79.5% | −2.6 |
| FY2017 | Dec 31, 2017 | 82.1% | +0.1 |
| FY2016 | Dec 31, 2016 | 82.0% | +534.0 |
| FY2015 | Dec 31, 2015 | -452.0% | +290.2 |
| FY2014 | Dec 31, 2014 | -742.2% | −162.3 |
| FY2013 | Dec 31, 2013 | -579.9% | +41.0 |
| FY2012 | Dec 31, 2012 | -620.9% | −710.4 |
| FY2011 | Dec 31, 2011 | 89.5% | −2.7 |
| FY2010 | Dec 31, 2010 | 92.2% | +1.7 |
| FY2009 | Dec 31, 2009 | 90.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | 78.8% | −9.0 |
| Q4 FY2025 | Dec 31, 2025 | 83.6% | +2.6 |
| Q3 FY2025 | Sep 30, 2025 | 88.1% | +2.6 |
| Q2 FY2025 | Jun 30, 2025 | -428.2% | −510.8 |
| Q1 FY2025 | Mar 31, 2025 | 87.8% | +6.4 |
| Q4 FY2024 | Dec 31, 2024 | 81.1% | −2.6 |
| Q3 FY2024 | Sep 30, 2024 | 85.4% | +2.9 |
| Q2 FY2024 | Jun 30, 2024 | 82.6% | −3.4 |
| Q1 FY2024 | Mar 31, 2024 | 81.5% | −5.0 |
| Q4 FY2023 | Dec 31, 2023 | 83.6% | +12.7 |
| Q3 FY2023 | Sep 30, 2023 | 82.5% | +2.0 |
| Q2 FY2023 | Jun 30, 2023 | 86.0% | +5.8 |
| Q1 FY2023 | Mar 31, 2023 | 86.4% | +6.2 |
| Q4 FY2022 | Dec 31, 2022 | 71.0% | +10.9 |
| Q3 FY2022 | Sep 30, 2022 | 80.5% | −3.0 |
| Q2 FY2022 | Jun 30, 2022 | 80.3% | −0.5 |
| Q1 FY2022 | Mar 31, 2022 | 80.2% | +3.1 |
| Q4 FY2021 | Dec 31, 2021 | 60.0% | −17.9 |
| Q3 FY2021 | Sep 30, 2021 | 83.5% | +6.7 |
| Q2 FY2021 | Jun 30, 2021 | 80.8% | +8.0 |
| Q1 FY2021 | Mar 31, 2021 | 77.1% | −3.3 |
| Q4 FY2020 | Dec 31, 2020 | 77.9% | +3.6 |
| Q3 FY2020 | Sep 30, 2020 | 76.8% | −0.4 |
| Q2 FY2020 | Jun 30, 2020 | 72.8% | −8.2 |
| Q1 FY2020 | Mar 31, 2020 | 80.4% | −0.6 |
| Q4 FY2019 | Dec 31, 2019 | 74.3% | −14.5 |
| Q3 FY2019 | Sep 30, 2019 | 77.2% | −5.6 |
| Q2 FY2019 | Jun 30, 2019 | 81.0% | −4.0 |
| Q1 FY2019 | Mar 31, 2019 | 81.0% | −1.2 |
| Q4 FY2018 | Dec 31, 2018 | 88.8% | +7.3 |
| Q3 FY2018 | Sep 30, 2018 | 82.8% | +2.2 |
| Q2 FY2018 | Jun 30, 2018 | 85.0% | +4.3 |
| Q1 FY2018 | Mar 31, 2018 | 82.2% | −3.5 |
| Q4 FY2017 | Dec 31, 2017 | 81.5% | −0.8 |
| Q3 FY2017 | Sep 30, 2017 | 80.7% | +3.1 |
| Q2 FY2017 | Jun 30, 2017 | 80.7% | – |
| Q1 FY2017 | Mar 31, 2017 | 85.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 82.3% | – |
| Q3 FY2016 | Sep 30, 2016 | 77.5% | – |
See a number that looks wrong?